Successful use of biweekly gemcitabine plus nab-paclitaxel in two male patients with stage IV breast cancer

Case reports and review of the literature

Alberto J. Montero, Tony N. Talebi, Ying Zhu, Kevin D. Branch, Grant T. Goldsberry, Megan K. Baker, Stefan Gluck

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Male breast cancer is a rare disease. As a consequence, male breast cancer is often recognized later, and most patients present at an advanced clinical stage. We report the cases of two men with stage IV hormone receptor positive breast cancer who had both received at different times both systemic endocrine therapy with an aromatase inhibitor and gemcitabine as well as nab-paclitaxel-based combination chemotherapy. Although the aromatase inhibitors such as anastrozole, exemestane, and letrozole are very active in postmenopausal women with hormone receptor positive breast cancer, their efficacy in male breast cancer has not been demonstrated in phase II or III trials. Moreover, Gemcitabine and nab-paclitaxel every 14 days, with or without bevacizumab, are an active combination in male metastatic breast cancer and should be considered as an option in patients with extensive visceral metastases or hormone refractory disease.

Original languageEnglish
JournalAmerican Journal of Therapeutics
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

gemcitabine
Male Breast Neoplasms
Breast Neoplasms
Aromatase Inhibitors
exemestane
letrozole
Hormones
Rare Diseases
Combination Drug Therapy
Neoplasm Metastasis
130-nm albumin-bound paclitaxel

Keywords

  • abraxane
  • circulating tumor cells
  • gemcitabine
  • male breast cancer
  • nab-paclitaxel

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Successful use of biweekly gemcitabine plus nab-paclitaxel in two male patients with stage IV breast cancer : Case reports and review of the literature. / Montero, Alberto J.; Talebi, Tony N.; Zhu, Ying; Branch, Kevin D.; Goldsberry, Grant T.; Baker, Megan K.; Gluck, Stefan.

In: American Journal of Therapeutics, Vol. 18, No. 1, 01.01.2011.

Research output: Contribution to journalArticle

Montero, Alberto J. ; Talebi, Tony N. ; Zhu, Ying ; Branch, Kevin D. ; Goldsberry, Grant T. ; Baker, Megan K. ; Gluck, Stefan. / Successful use of biweekly gemcitabine plus nab-paclitaxel in two male patients with stage IV breast cancer : Case reports and review of the literature. In: American Journal of Therapeutics. 2011 ; Vol. 18, No. 1.
@article{a74275e66f554b9dbd856cc9aeef20e7,
title = "Successful use of biweekly gemcitabine plus nab-paclitaxel in two male patients with stage IV breast cancer: Case reports and review of the literature",
abstract = "Male breast cancer is a rare disease. As a consequence, male breast cancer is often recognized later, and most patients present at an advanced clinical stage. We report the cases of two men with stage IV hormone receptor positive breast cancer who had both received at different times both systemic endocrine therapy with an aromatase inhibitor and gemcitabine as well as nab-paclitaxel-based combination chemotherapy. Although the aromatase inhibitors such as anastrozole, exemestane, and letrozole are very active in postmenopausal women with hormone receptor positive breast cancer, their efficacy in male breast cancer has not been demonstrated in phase II or III trials. Moreover, Gemcitabine and nab-paclitaxel every 14 days, with or without bevacizumab, are an active combination in male metastatic breast cancer and should be considered as an option in patients with extensive visceral metastases or hormone refractory disease.",
keywords = "abraxane, circulating tumor cells, gemcitabine, male breast cancer, nab-paclitaxel",
author = "Montero, {Alberto J.} and Talebi, {Tony N.} and Ying Zhu and Branch, {Kevin D.} and Goldsberry, {Grant T.} and Baker, {Megan K.} and Stefan Gluck",
year = "2011",
month = "1",
day = "1",
doi = "10.1097/MJT.0b013e3181c219e2",
language = "English",
volume = "18",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Successful use of biweekly gemcitabine plus nab-paclitaxel in two male patients with stage IV breast cancer

T2 - Case reports and review of the literature

AU - Montero, Alberto J.

AU - Talebi, Tony N.

AU - Zhu, Ying

AU - Branch, Kevin D.

AU - Goldsberry, Grant T.

AU - Baker, Megan K.

AU - Gluck, Stefan

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Male breast cancer is a rare disease. As a consequence, male breast cancer is often recognized later, and most patients present at an advanced clinical stage. We report the cases of two men with stage IV hormone receptor positive breast cancer who had both received at different times both systemic endocrine therapy with an aromatase inhibitor and gemcitabine as well as nab-paclitaxel-based combination chemotherapy. Although the aromatase inhibitors such as anastrozole, exemestane, and letrozole are very active in postmenopausal women with hormone receptor positive breast cancer, their efficacy in male breast cancer has not been demonstrated in phase II or III trials. Moreover, Gemcitabine and nab-paclitaxel every 14 days, with or without bevacizumab, are an active combination in male metastatic breast cancer and should be considered as an option in patients with extensive visceral metastases or hormone refractory disease.

AB - Male breast cancer is a rare disease. As a consequence, male breast cancer is often recognized later, and most patients present at an advanced clinical stage. We report the cases of two men with stage IV hormone receptor positive breast cancer who had both received at different times both systemic endocrine therapy with an aromatase inhibitor and gemcitabine as well as nab-paclitaxel-based combination chemotherapy. Although the aromatase inhibitors such as anastrozole, exemestane, and letrozole are very active in postmenopausal women with hormone receptor positive breast cancer, their efficacy in male breast cancer has not been demonstrated in phase II or III trials. Moreover, Gemcitabine and nab-paclitaxel every 14 days, with or without bevacizumab, are an active combination in male metastatic breast cancer and should be considered as an option in patients with extensive visceral metastases or hormone refractory disease.

KW - abraxane

KW - circulating tumor cells

KW - gemcitabine

KW - male breast cancer

KW - nab-paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=78751658777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751658777&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e3181c219e2

DO - 10.1097/MJT.0b013e3181c219e2

M3 - Article

VL - 18

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 1

ER -